ZENTEC.NSE

Zen Technologies Ltd.

Hyderabad: Zen Technologies has unveiled a new indigenous platform that it describes as the country's first fully integrated, AI-powered anti-drone sy.

Zen Technologies Limited ( ($IN:ZENTEC) ) has provided an update. Zen Technologies Limited has unveiled what it calls India’s first AI-powered, ful...

Zen Technologies Limited ( ($IN:ZENTEC) ) has provided an update. Zen Technologies Limited has unveiled what it calls India’s first AI-powered, ful...

Zen Technologies Limited ( ($IN:ZENTEC) ) has issued an update. Zen Technologies Limited is an Indian technology company based in Hyderabad that fo...

In this briefing: APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 1. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev. Eisai’s Phase 3 trial evaluating Lenvima in RCC did not meet primary endpoints. Celltrion started patient dosing for three of its novel ADC-based anticancer drug candidates. Cochlear has reduced FY26 underlying net profit guidance to A$290–330M from A$435–460M. 2.

In this briefing: APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 1. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev. Eisai’s Phase 3 trial evaluating Lenvima in RCC did not meet primary endpoints. Celltrion started patient dosing for three of its novel ADC-based anticancer drug candidates. Cochlear has reduced FY26 underlying net profit guidance to A$290–330M from A$435–460M. 2.

In this briefing: HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 Primer: Krishna Institute of Medical Sciences (KIMS IN) - Apr 2026 1. HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Context: The Yes Bank (YES IN) vs. HDFC Bank (HDFCB IN) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity. Highlight: Going long HDFC Bank (HDFCB IN) and short Yes Bank (YES IN) targets a 7% return. Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play. 2. Primer: Exide Industries (EXID IN) - Apr 2026 Exide Industries is India's largest lead-acid battery manufacturer, strategically pivoting towards lithium-ion (Li-ion) cell production to capitalize on the electric vehicle (EV) and renewable energy storage boom.

In this briefing: HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 Primer: Krishna Institute of Medical Sciences (KIMS IN) - Apr 2026 1. HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Context: The Yes Bank (YES IN) vs. HDFC Bank (HDFCB IN) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity. Highlight: Going long HDFC Bank (HDFCB IN) and short Yes Bank (YES IN) targets a 7% return. Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play. 2. Primer: Exide Industries (EXID IN) - Apr 2026 Exide Industries is India's largest lead-acid battery manufacturer, strategically pivoting towards lithium-ion (Li-ion) cell production to capitalize on the electric vehicle (EV) and renewable energy storage boom.

In this briefing: Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 Primer: Krishna Institute of Medical Sciences (KIMS IN) - Apr 2026 Higher Import Prices and Modest Export Rebound to Push CAD to 1% of GDP in FY27 1. Primer: Exide Industries (EXID IN) - Apr 2026 Exide Industries is India's largest lead-acid battery manufacturer, strategically pivoting towards lithium-ion (Li-ion) cell production to capitalize on the electric vehicle (EV) and renewable energy storage boom. The company is undertaking significant capital expenditure to establish a 12 GWh Li-ion cell manufacturing plant through its subsidiary, Exide Energy Solutions Ltd. (EESL), which presents a substantial long-term growth opportunity but also carries execution risk and is expected to suppress free cash flow in the near term. While maintaining a dominant position in the profitable lead-acid aftermarket, which provides stable cash flows, the company faces increasing competition in the emerging Li-ion space and margin pressures from raw material price volatility.